C71T
CANCELLED SECTION 71
03/06/2026
Back to search
Official data from USPTO
AQIX
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
50
Latest update
03/31/2026
Trademark type
Word
Nice classes
1, 5, 42
Filing date
05/03/2013
Registration date
01/28/2014
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
03/06/2026
Last transaction
03/31/2026
Responsible office
United States Patent and Trademark Office
Status code
709
Official register
Principal Register
Drawing code
4
Owner type
99
Owner location
GB
Examiner
ALVAREZ, COURTNEY
Law office
L80
Current location
GENERIC WEB UPDATE
Holders and representatives
Holders
Aqix Limited
Representatives
Tracy Deutmeyer Fredrikson & Byron, P.A.
Technical classification
Nice Classes
Class 1Class 5Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Chemicals for use in scientific analysis; chemicals for scientific purposesmaking pharmaceutical and veterinary preparationsbeing media for storing organstissue and cells; cellbacteria and virus growth media for use with cellbacterial and viral cultures in scientific research
Class 5
Solutions for medical and clinical use in supporting human and animal cellstissue and organs; solutions for medical and clinical use and application in infusion therapyorgan transplant perfusion and cell or tissue bio-specimen collection and preservationsuch preservation being to preserve stem cells and their therapeutic applications; solutions for intravenous use for medicalsurgical and veterinary purposes; cultures for growing cellsbacteria and viruses for medical and clinical purposes; solutions for medical and clinical use for replacingsynthesizingdilutingrehydrating and expanding human and animal bloodintravascular and extravascular fluids; solutions for medical and clinical use for cellorgan and tissue preservation and the creation of a homeostasis to regulate the environment of cellsorgans and tissues; solutions for medical and clinical use for testing drugs on ex vivo perfused human and animal cellstissue and organs; cellbacteria and virus growth mediastorage media and transportation media for medical or clinical use for stem cell and DNA research and therapy; pharmaceutical transfer agents or components for pharmaceuticals in the form of solutions for medical use for application in infusion therapyorgan transplant perfusion and cell or tissue bio-specimen collection and preservation; tissue regenerative pharmaceutical preparations and solutions; stem cells for medical and veterinary purposes; clinical diagnostic preparations for medical or veterinary use; clinical medical reagents; medical diagnostic reagents for proteomicgenomic and metabolomic analysis of tissuescellsbacteria and viruses and testing the stability of homeostasis within organstissuescellsbacteria and viruses for medical use; * none of the aforesaid * being or * relating to ready-made pharmaceuticals * substancespreparationscompositions or solutions * and none of the aforesaid * being * for use in connection with the * detection or * treatment of herpes and related viral diseases *for use with tissue or organs infected by herpes or related viral diseases *
Class 42
Laboratory services for analytical testing; laboratory services relating to the researching of pharmaceuticals and solutions for medical and surgical use and solutions for supporting human and animal cellstissue and organssolutions for use and application in infusion therapyorgan transplant perfusion and cell or tissue bio-specimen collection and preservationsolutions for storing human and animal organstissues and cellssolutions for replacingsynthesizingdilutingrehydrating and expanding human and animal bloodintravascular and extravascular fluidssolutions for testing drugs on human and animal cellstissue and organsmedia for stem cell and DNA research and therapy; scientific research; medical transplant research services; medical research; scientific analysis of human tissue and human serum for medical research; stem cell and DNA scientific and medical research services; chemical research and development services; chemicalmedical and scientific testing and analysis for medical research purposes; testing of pharmaceutical solutions for medical research purposes; quality control services for others; clinical medical and scientific research; conducting of clinical trials for others; design and development of new technology and products for other uses in medical and veterinary fields; Informationadvisory and consultancy services relating to all of the aforesaid * laboratory services for analytical testing and to scientific research *
Publications
History of USPTO decisions and trademark events.
50 publications found
RNWL
INTERNATIONAL REGISTRATION RENEWED
10/12/2023
REM4
COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED
01/28/2023
NCP7
NOTICE OF PARTIAL CANCELLATION SEC. 7 SURRENDER EMAILED
02/05/2021
NA75
NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED
02/04/2021
C75A
REGISTERED - SEC. 71 ACCEPTED & SEC. 15 ACK.
02/04/2021
C7P.
CANCELLED SEC. 7 - PARTIAL
02/04/2021
NREP
NEW REPRESENTATIVE AT IB RECEIVED
12/18/2020
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
11/25/2020
ES75
TEAS SECTION 71 & 15 RECEIVED
07/28/2020
ES7R
TEAS SECTION 7 REQUEST RECEIVED
07/28/2020
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
01/28/2019
INNA
INVALIDATION REVIEWED - NO ACTION REQUIRED BY OFFICE
04/13/2018
INPR
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
04/10/2018
COC.
CORRECTION UNDER SECTION 7 - PROCESSED
08/10/2017
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
08/10/2017
LIME
LIMITATION FROM THE IB EXAMINED AND ENTERED
08/10/2017
LIMG
LIMITATION OF GOODS RECEIVED FROM IB
06/16/2017
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
10/27/2016
INNA
INVALIDATION REVIEWED - NO ACTION REQUIRED BY OFFICE
03/12/2016
INPR
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
01/07/2016
COC.
CORRECTION UNDER SECTION 7 - PROCESSED
05/07/2015
PLGL
ASSIGNED TO PARALEGAL
05/07/2015
LIME
LIMITATION FROM THE IB EXAMINED AND ENTERED
05/07/2015
LIMG
LIMITATION OF GOODS RECEIVED FROM IB
05/01/2015
NREP
NEW REPRESENTATIVE AT IB RECEIVED
11/14/2014
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
07/04/2014
FICS
FINAL DISPOSITION NOTICE SENT TO IB
06/17/2014
FIMP
FINAL DISPOSITION PROCESSED
06/17/2014
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
04/28/2014
R.PR
REGISTERED-PRINCIPAL REGISTER
01/28/2014
NREP
NEW REPRESENTATIVE AT IB RECEIVED
12/13/2013
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
11/12/2013
PUBO
PUBLISHED FOR OPPOSITION
11/12/2013
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
10/23/2013
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
10/08/2013
ALIE
ASSIGNED TO LIE
10/07/2013
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
09/25/2013
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
09/24/2013
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
09/24/2013
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
09/24/2013
RFNT
REFUSAL PROCESSED BY IB
09/17/2013
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
08/27/2013
RFRR
REFUSAL PROCESSED BY MPU
08/27/2013
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
08/25/2013
CNRT
NON-FINAL ACTION WRITTEN
08/24/2013
DOCK
ASSIGNED TO EXAMINER
08/22/2013
MAFR
APPLICATION FILING RECEIPT MAILED
08/13/2013
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
08/09/2013
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
08/08/2013
Continuous trademark protection
Get notified about every new filing that threatens AQIX or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.